Koo Foundation Sun Yat-Sen Cancer Center
16
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.8%
3 terminated/withdrawn out of 16 trials
57.1%
-29.4% vs industry average
25%
4 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Cancer Survivors' Fear of Cancer Recurrence
Role: collaborator
Fighting the Fear of Cancer Recurrence in Cancer Survivors: A Pilot Study on the Effectiveness of Metacognitive Therapy
Role: lead
The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer
Role: collaborator
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
Role: collaborator
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Role: lead
Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA
Role: lead
A RCT of Psychosocial Interventions Facilitating Positive Psychological Adaptation in Breast Cancer
Role: lead
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Role: lead
RhD+ Blood Transfusion to Asian-type DEL Recipients
Role: collaborator
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Role: collaborator
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Role: collaborator
Environmental and Genetic Determinants of NPC
Role: collaborator
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
Role: collaborator
Chinese TaTME Registry Collaborative
Role: collaborator
Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma
Role: collaborator
Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients
Role: collaborator
All 16 trials loaded